Company announcement,
The Shareholder’s Nomination
The Nomination Board proposes to the Annual General Meeting that:
- in accordance with their consents to serving on the Board, Mr.
Martin Forss , Ms. Leena Niemistö Mr. Tero Weckroth and Mr.Timo Hildén shall be re-elected as members of the Board. Leena Niemistö is elected as Chair of the Board.
The biographies of Board members are visible in the Company’s website.
The Nomination Board agrees that proposed new Board members and the entire Board are suitable for the proposed roles individually and collectively, and
The Nomination Board proposes that the members of the Board of Directors chosen in the Annual General Meeting be remunerated for the period ending at the end of the 2023 Annual General Meeting as follows:
- €36,000 for the Chairman of the Board;
- €25,200 for other members of the Board; and
No member of the Board of Directors serving in the Nomination
According to the company’s policy, the cash remuneration is paid in four instalments.
Restricted Share Unit Plan and Allocation for Board Members
The Nomination proposes to the Annual General Meeting that
the restricted share unit plan implemented first in 2016 be continued for one year for the seventh vesting period (2022–2023) with respect to the elected members of the Board of Directors of
the target group of the plan be those members of the Board of Directors who are independent of the company. Such a member is, however, not required to be independent of the major shareholders of the company
the rewards allocations in 2022 will be determined as a Euro value
The aim of the plan is to commit the participants to the company, align the objectives of shareholders and participants and thereby increase the value of the company and to offer the participants a reward plan based on receiving and accumulating the company’s shares.
Allocation for Board Members for the Vesting Period 2022–2023
The Nomination Board proposes to the Annual General Meeting that:
- for a Board member, the gross value of the compensation for the vesting period 2022–2023 will be as follows:
- for the chairman of the Board of Directors: €24,000
- for a member: €16,800
The granted compensation will be converted into restricted share units at the beginning of the vesting period in 2022. The conversion of the granted reward into restricted share units will be based on the trade-volume-weighted average quotation of the company’s share on
The Nomination Board proposes that the compensations pursuant to the plan be paid to the Board Members in the company’s shares within one month of the Annual General Meeting of Shareholders in 2023. Should a Board Member cease to be a member of the Board before the end of a vesting period, no compensation will be paid on that basis.
The company will withhold taxes and employment-related expenses from the cash proportion of the compensation as per applicable law.
Ownership recommendation
The Nomination
Travel expenses
In addition, the Nomination Board proposes that reasonable travel expenses be reimbursed against receipts to the members of the Board, following the principles of the company’s Travel Policy. This applies both to members of the Board of Directors and, to the extent applicable, Board members acting as members of the Nomination
Nomination Board of the Shareholders
Further information is available on the website www.nexstim.com or by contacting:
+358 9 2727 170
leena.niemisto@nexstim.com
Erik Penser
+46 8 463 83 00
certifiedadviser@penser.se
About
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in
For more information, please visit www.nexstim.com
Attachment
- CA_Nimitystoimikunnan ehdotukset yhtiökokoukselle_28022022_ENG_FINAL
© OMX, source